Skip to main content
SpringerLink
Log in

Complications cardiovasculaires des inhibiteurs des cholinestérases

  • Chapter
Book cover Traité sur la maladie d’Alzheimer

  • 901 Accesses

Résumé

Les effets secondaires cardiovasculaires des médicaments anticholinestérasiques sont une préoccupation fréquente pour les gériatres traitant des pathologies cognitives.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ferreri F, Agbokou C, Gauthier S (2007) Mise au point: effets cardiovasculaires des inhibiteurs de la cholinesterase dans la maladie d’Alzheimer. Rev Neurol 163: 968–74

    Article  CAS  PubMed  Google Scholar 

  2. Tavassoli N, Sommet A, Lapeyre-Mestre M., et al. (2007) Drugs interactions with cholinesterase inhibitors. Drug Safety 30(11): 1063–71

    Article  CAS  PubMed  Google Scholar 

  3. Bordier P, Lanusse S, Garrigue S, et al. (2005) Cause of syncope in patients with Alzheimer disease treated with Donapezil. Drugs Aging 22: 687–94

    Article  CAS  PubMed  Google Scholar 

  4. World Health Organisation (2004) Cholinesterase inhibitors and cardiac arythmias. WHO Drug Information — Safety and Efficacy issues 18: 273–4

    Google Scholar 

  5. Brembillat-Peyrot B, Regent MC, Hanesse B. et al. (2004) Troubles de la conduction auriculo-ventriculaires paroxystiques liés à la prise d’un anticholinestérasique. Arch Mal Coeur Vaiss 97: 1265–7

    Google Scholar 

  6. Hernandez RK, Farwell W., Cantor MD, Lawler EV (2009) Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc 57: 1997–2003

    Article  PubMed  Google Scholar 

  7. Pratt RD, Perdomo CA, Surick IW (2002) Donepezil: tolerability and safety in Alzheimer disease. Int J Clin Pract 56710–7

    Google Scholar 

  8. Ballard C, Lane R, Barone P. et al. (2006) Cardiac safety of rivastigmine in Lewy body and Parkinson disease dementia. Int J Clin Pract 60: 639–45

    Article  CAS  PubMed  Google Scholar 

  9. Park-Willie LY, Mamdani MM, Li P, et al. (2009) Cholinesterase inhibitors and hospitalization for bradycardia: a population based study. PLOS medicine 6(9): 1–9

    Google Scholar 

  10. Gill SS, Anderson GM, Fischer HD, et al. (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. Arch Intern Med 169: 867–73

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de cardiogériatrie, Pôle gériatrie, CHU Toulouse, France

    B. Fontan & O. Toulza

Authors
  1. B. Fontan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Toulza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Fontan .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Fontan, B., Toulza, O. (2013). Complications cardiovasculaires des inhibiteurs des cholinestérases. In: Traité sur la maladie d’Alzheimer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0443-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0443-9_16

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0442-2

  • Online ISBN: 978-2-8178-0443-9

Publish with us

Policies and ethics

Search

Navigation